| Vol. 10.12 – 1 April, 2021 |
| |
|
|
| Scientists investigated the role of CD148 in the profibrotic phenotype of fibroblasts in idiopathic pulmonary fibrosis. Conditional CD148 fibroblast-specific knockout mice were generated and exposed to bleomycin, and then assessed for pulmonary fibrosis. [American Journal of Respiratory and Critical Care Medicine] |
|
|
|
| PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Researchers used CRISPR/Cas9 and two adeno-associated viruses carrying the two halves of the cystic fibrosis transmembrane conductance regulator (CFTR) cDNA to sequentially insert the full CFTR cDNA along with a truncated CD19 enrichment tag in upper airway basal stem cells and human bronchial basal stem cells. [Molecular Therapy] |
|
|
|
| Since different temperatures encountered in the human upper and lower respiratory tract have been shown to affect the replication kinetics of several respiratory viruses, as well as host immune response dynamics, the authors investigated the impact of temperatures during SARS-CoV-2 and SARS-CoV infection using the primary human airway epithelial cell culture model. [PLoS Biology] |
|
|
|
| Using mouse and cell culture models, scientists evaluated the effects of incense smoke exposure on airway hyperresponsiveness, expression of multiple epithelial tight junction- and adherens junction-associated mRNAs and proteins in the lungs, and the barrier function of bronchial epithelial cells assessed by transepithelial electronic resistance. [Scientific Reports] |
|
|
|
|
| miR-196a-overexpressed lung fibroblasts (LF-196a) promoted the migration and invasion of lung cancer cells in co-culture systems. ANXA1 was confirmed as a direct target of miR-196a, and adding back ANXA1 to LF-196a restored the cancer cell invasion promoted by miR-196a. [Cancer Letters] |
|
|
|
| The authors report the implementation of CRISPR/Cas-9 genetic screening to identify susceptibilities of multiple A3A-expressing lung adenocarcinoma cell lines. [PLoS Biology] |
|
|
|
| miR‑454‑3p overexpression led to the suppression of proliferation, migration, and invasion in A549 and NCI‑H1650 cells. The overexpression of miR‑454‑3p in A549 and NCI‑H1650 cells significantly inhibited EMT. TGFB2 was revealed to be a direct target of miR‑454‑3p by using TargetScan database and luciferase reporter assay. [Oncology Reports] |
|
|
|
| Researchers demonstrated that tissue‑specific transplantation antigen P35B (TSTA3) was regulated by miR‑125a‑5p and functions as an oncogene in lung cancer via promoting the activation of β‑catenin signaling. [Oncology Reports] |
|
|
|
| Functional experiments showed that MCF2L‐AS1 knockdown suppressed the cancer stem cell‐like traits of non-small cell lung cancer cells through qRT‐PCR, western blot, tumor‐sphere formation, and ALDH activity detection. [Environmental Toxicology] |
|
|
|
| PC9 and HCC827 non‐small cell lung cancer cell lines were treated with high concentrations of gefitinib, and surviving cells were referred to as “gefitinib‐resistant persisters” (GRPs). Zinc‐finger E‐box‐binding homeobox 1 (ZEB1) knockdown or overexpression was performed to determine the biological significance of ZEB1 in the cancer stem cell features of GRPs, and animal models were studied for in vivo validation. [Thoracic Cancer] |
|
|
|
|
| The authors explore current diagnostic problems of gene fusion detection relative to the technologies available, in order to clarify future standardization of analyses which determine therapeutic choices. [Expert Review of Anticancer Therapy] |
|
|
|
|
| Roche announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended the approval of Tecentriq® as a first-line treatment for adults with metastatic non-small cell lung cancer whose tumors have high PD-L1 expression, with no epidermal growth factor receptor or anaplastic lymphoma kinase genomic tumor aberrations. [Roche] |
|
|
|
|
| May 12 – 14, 2021 Virtual |
|
|
|
|
|
| Hannover Medical School – Hannover, Germany |
|
|
|
| United Therapeutics Corporation – Manchester, New Hampshire, United States |
|
|
|
| Thomas Jefferson University – Philadelphia, Pennsylvania, United States |
|
|
|
| Translate Bio, Inc. – Lexington, Massachusetts, United States |
|
|
|
| Brigham and Woman’s Hospital – Boston, Massachusetts, United States |
|
|
|
|